Register Login

Abiopharma

  • Home
  • About
  • Newsroom
  • Company List
  • Events
  • Automated Tools
  • Contact

News list

INMUNE BIO, INC. (INMB)

  • Business News
  • June 25, 2026, 11:00 UTC
  • 5
  • 1 comments

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™

Market reaction Comment Full text

YIREN DIGITAL LTD. (YRD)

  • Business News
  • June 25, 2026, 11:00 UTC
  • 5
  • 1 comments

Yiren Digital Reports First Quarter 2026 Unaudited Financial Results

Market reaction Comment Full text

NUVATION BIO INC. (NUVB)

  • Business News
  • June 25, 2026, 11:00 UTC
  • 3
  • 1 comments

Nuvation Bio Announces Proposed Convertible Senior Notes Offering

Market reaction Comment Full text

HIGHLANDER SILVER CORP. (HSLV)

  • Business News
  • June 25, 2026, 11:00 UTC
  • 5
  • 1 comments

Highlander Silver: Comprehensive Geophysical Program Maps Extensive System Concealed by Shallow Cover at Corani

Market reaction Comment Full text

CANADIAN SOLAR INC. (CSIQ)

  • Business News
  • June 25, 2026, 11:00 UTC
  • 4
  • 1 comments

e‑STORAGE to Deliver 426 MWh of Energy Storage in Florida

Market reaction Comment Full text

ISOENERGY LTD. (ISOU)

  • Business News
  • June 25, 2026, 11:00 UTC
  • 4
  • 1 comments

IsoEnergy Completes Acquisition of Toro Energy

Market reaction Comment Full text

INSULET CORP (PODD)

  • Business News
  • June 25, 2026, 11:00 UTC
  • 2
  • 1 comments

Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors

Market reaction Comment Full text

DOLLAR TREE, INC. (DLTR)

  • Business News
  • June 25, 2026, 11:00 UTC
  • 6
  • 1 comments

Dollar Tree Announces Secondary Block Trade by Selling Stockholders and Share Buyback

Market reaction Comment Full text

CONSTELLATION ENERGY CORP (CEG)

  • Business News
  • June 25, 2026, 11:00 UTC
  • 3
  • 1 comments

Constellation Announces Extension of Expiration for Exchange Offers

Market reaction Comment Full text

GLAUKOS CORP (GKOS)

  • Business News
  • June 25, 2026, 11:00 UTC
  • 6
  • 1 comments

Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis

Market reaction Comment Full text
  • Previous
  • 3108
  • 3109
  • 3110
  • 3111
  • 3112
  • Next

Search

News categories

  • Technical Exchange News(14433)
  • Event(6229)
  • SEC News(377732)
  • FDA Approval(10304)
  • Company Report(721)
  • Business News(231029)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin